Generated by AI
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered biologic therapies for oncology and other serious diseases. Inhibrx Biosciences uses proprietary protein engineering platforms to design multivalent therapeutic candidates that are intended to interact precisely with complex biological targets. Its current pipeline centers on ozekibart (INBRX-109) and INBRX-106, programs being advanced in clinical studies across solid tumors and rare cancer settings. The company’s work is directed toward creating targeted medicines that address difficult-to-treat conditions through differentiated biologic mechanisms. Headquartered in La Jolla, California, Inhibrx Biosciences plays a specialized role in the biopharmaceutical market as a developer of precision protein-based therapeutics.
Website11025 North Torrey Pines Road
La Jolla, CA, 92037
United States
The latest articles about INBX.
Inhibrx Biosciences recently announced that it will present updated data on its clinical-stage candidates INBRX-106 and INBRX-109 from phase 2/3 and phase 2 studies in head and neck squamous cell carcinoma and conventional chondrosarcoma at major oncology and tumor society conferences in Europe, the US, and South Korea. This cluster of high-profile scientific presentations, with materials to be shared on the company’s investor website, highlights how Inhibrx is bringing its clinical data...
Summary of Oct 28's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Summary of Apr 22's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about INBX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.